<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076512/results/search/drug/results.xml">
  <result pre="humans, includes highly selective and effective antivirals, from which only" exact="acyclovir" post="(ACV) and ganciclovir (GCV) were incorporated into nanomaterials; a"/>
  <result pre="selective and effective antivirals, from which only acyclovir (ACV) and" exact="ganciclovir" post="(GCV) were incorporated into nanomaterials; a complete classification of"/>
  <result pre="used, either alone or in combination [57]. These include also" exact="amantadine" post="and neuraminidase inhibitors (zanamivir and oseltamivir), that have been"/>
  <result pre="against influenza virus infection [58,59,60]. Briefly, the antiviral mechanism of" exact="amantadine" post="is based on nterference with the viral protein, M2"/>
  <result pre="included/encapsulated/incorporated into nanomaterials. The representative nucleoside reverse transcriptase inhibitor (NRTI)" exact="zidovudine" post="(AZT) is phosphorylated intracellular by kinases specific to AZT"/>
  <result pre="41, 44, 67, 70, 210, 215, and 219 [72]. Also," exact="lamivudine" post="(LAM), another NRTI agent, enters cells by passive diffusion,"/>
  <result pre="by deoxycytidine monophosphate kinase and nucleoside diphosphate kinase to yield" exact="lamivudine" post="5′-triphosphate, which is the active anabolite [73]. Tenofovir disoproxil"/>
  <result pre="the active anabolite [73]. Tenofovir disoproxil is a derivative of" exact="adenosine" post="5′-monophosphate lacking a complete ribose ring, and it is"/>
  <result pre="infectious form [77,78]. Only SQV, indinavir, ATV, RTV, NFV and" exact="lopinavir" post="are currently employed in nanotechnology research. There are two"/>
  <result pre="this case for the topical form of trifluridine (TFT) and" exact="ganciclovir" post="(ACV analog) gels, is denoted by low retention time"/>
  <result pre="on the membrane [113]; transferrin-conjugated quantum rod nanoparticles conjugated with" exact="saquinavir" post="crossed an in vitro BBB model by exploiting a"/>
  <result pre="having the ability to inhibit the replication of HSV-1 (both" exact="acyclovir" post="sensitive and resistant strains) and also some strains of"/>
  <result pre="poly(lactic-co-glycolic acid)-polyethylene glycol diblock copolymers and anti-CD45RO antibody conjugated with" exact="suberoylanilide hydroxamic acid" post="(SAHA) and NFV and tested theirs in vitro properties"/>
  <result pre="adults who are currently receiving anti-HIV treatment (number NCT00270205) [194];" exact="Doravirine" post="(MK-1439), from Merck, a novel, next generation NNRTI described"/>
  <result pre="described as solid drug nanoparticle formulation tested for HIV; currently" exact="doravirine" post="completed the pharmacokinetic trial of the bioavailability of four"/>
  <result pre="doravirine completed the pharmacokinetic trial of the bioavailability of four" exact="MK-1439" post="nano formulations in healthy adults (number NCT02549040) [195]; Lipid"/>
  <result pre="LNPs: lipid nanoparticles; MNPs: magnetic nanoparticles; MPEG: N-(carbonylmethoxypolyethyleneglycol-2000); DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine," exact="sodium salt;" post="MTT: [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide]; MTS: [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]; NaDC: sodium deoxycholate; NEs:"/>
  <result pre="carboxymethylcellulose; SLNs: solid lipid nanoparticles; SLS: sodium lauryl sulphate; SAHA:" exact="suberoylanilide hydroxamic acid;" post="SEM: scanning electron microscopy; SeNPs: selenium nanoparticles; Se@AM: selenium"/>
  <result pre="RNA; ssDNA: single stranded DNA; ssRNA: single stranded RNA; TAF:" exact="tenofovir alafenamide;" post="TEM: transmission electron microscopy; Tf: transferrin; TFV: tenofovir; UNAIDS:"/>
  <result pre="foscarnet therapy remodels thymidine analogue mutations and alters resistance to" exact="zidovudine" post="and lamivudine in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral"/>
  <result pre="remodels thymidine analogue mutations and alters resistance to zidovudine and" exact="lamivudine" post="in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral for herpes"/>
  <result pre="A topical antiviral for herpes labialisExp. Opin. Pharmacother.200452567257110.1517/14656566.5.12.2567 51.MillerW.H.MillerR.L.Phosphorylation of" exact="acyclovir" post="diphosphate by cellular enzymesBiochem. Pharmacol.1982313879388410.1016/0006-2952(82)90305-77159465 52.KingD.H.History, pharmacokinetics, and pharmacology"/>
  <result pre="A (H5N1) InfectionN. Engl. J. Med.20053532667267210.1056/NEJMoa05451216371632 64.TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol. Hepatol.20073218225 65.KrečmerováM.Amino"/>
  <result pre="DNA Virus and Retrovirus InfectionsClin. Microbiol. Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of" exact="entecavir" post="for the treatment of chronic hepatitis B infection in"/>
  <result pre="State of the ArtIJMS201819154910.3390/ijms1906154929882846 90.collab: Herpetic Eye Disease Study GroupOral" exact="acyclovir" post="for herpes simplex virus eye disease: Effect on prevention"/>
  <result pre="112.KuoY.-C.ChenH.-H.Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of" exact="zidovudine" post="and lamivudine across the in vitro blood–brain barrierInt. J."/>
  <result pre="nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of zidovudine and" exact="lamivudine" post="across the in vitro blood–brain barrierInt. J. Pharm.200632716016910.1016/j.ijpharm.2006.07.04416939704 113.MishraV.MahorS.RawatA.GuptaP.N.DubeyP.KhatriK.VyasS.P.Targeted"/>
  <result pre="HIV reservoirsEur. J. Pharm. Biopharm.2019138486310.1016/j.ejpb.2018.06.00229879528 125.ShenY.TuJ.Preparation and ocular pharmacokinetics of" exact="ganciclovir" post="liposomesAAPS J.20079E37110.1208/aapsj090304418170984 126.FengM.CaiQ.ShiX.HuangH.ZhouP.GuoX.Recombinant high-density lipoprotein complex as a targeting"/>
  <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathwaysIJN2018132005201610.2147/IJN.S15599429662313 136.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium"/>
  <result pre="Proteic DrugsJ. Nanosci. Nanotechnol.200663040304710.1166/jnn.2006.41217048516 140.KumarP.LakshmiY.S.BhaskarC.GollaK.KondapiA.K.Improved Safety, Bioavailability and Pharmacokinetics of" exact="Zidovudine" post="through Lactoferrin Nanoparticles during Oral Administration in RatsPLoS ONE201510e014039910.1371/journal.pone.014039926461917"/>
  <result pre="Administration in RatsPLoS ONE201510e014039910.1371/journal.pone.014039926461917 141.KirimlioğluG.Y.ÖztürkA.A.Preparation and in vitro characterization of" exact="lamivudine" post="loaded nanoparticles prepared by acid and/or ester terminated PLGA"/>
  <result pre="of Zidovudine-Lamivudine NanoparticlesIndian J. Pharm. Educ. Res.201246192196 143.ShahL.K.AmijiM.M.Intracellular Delivery of" exact="Saquinavir" post="in Biodegradable Polymeric Nanoparticles for HIV/AIDSPharm. Res.2006232638264510.1007/s11095-006-9101-716969696 144.TangX.LiangY.LiuX.ZhouS.LiuL.ZhangF.XieC.CaiS.WeiJ.ZhuY.et al.PLGA-PEG"/>
  <result pre="Viral SpreadNanoscale Res. Lett.20151041310.1186/s11671-015-1112-z26489856 145.VenkateshD.N.BaskaranM.KarriV.V.S.R.MannemalaS.S.RadhakrishnaK.GotiS.Fabrication and in vivo evaluation of" exact="Nelfinavir" post="loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic"/>
  <result pre="inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyNanomedicine20161210912210.1016/j.nano.2015.09.00926472049 148.SavageA.C.TathamL.M.SiccardiM.ScottT.VourvahisM.ClarkA.RannardS.P.OwenA.Improving" exact="maraviroc" post="oral bioavailability by formation of solid drug nanoparticlesEur. J."/>
  <result pre="in Humanized Mice ModelPharm. Res.2017342749275510.1007/s11095-017-2255-728905173 151.KumarP.LakshmiY.S.KondapiA.K.Triple Drug Combination of Zidovudine," exact="Efavirenz" post="and Lamivudine Loaded Lactoferrin Nanoparticles: An Effective Nano First-Line"/>
  <result pre="Mice ModelPharm. Res.2017342749275510.1007/s11095-017-2255-728905173 151.KumarP.LakshmiY.S.KondapiA.K.Triple Drug Combination of Zidovudine, Efavirenz and" exact="Lamivudine" post="Loaded Lactoferrin Nanoparticles: An Effective Nano First-Line Regimen for"/>
  <result pre="Templating for the Topical Treatment of Herpesviruses InfectionsPharmaceutics2018104610.3390/pharmaceutics10020046 156.PatelG.V.PatelV.B.PathakA.RajputS.J.Nanosuspension of" exact="efavirenz" post="for improved oral bioavailability: Formulation optimization, in vitro, in"/>
  <result pre="Dev. Ind. Pharm.201440809110.3109/03639045.2012.74636223323843 157.AkhterS.TalegaonkarS.KhanZ.I.JainG.K.KharR.K.AhmadF.J.Assessment of Ocular Pharmacokinetics and Safety of" exact="Ganciclovir" post="Loaded NanoformulationsJ. Biomed. Nanotechnol.2011714414510.1166/jbn.2011.124121485843 158.RenJ.ZouM.GaoP.WangY.ChengG.Tissue distribution of borneol-modified ganciclovir-loaded"/>
  <result pre="160.KovochichM.MarsdenM.D.ZackJ.A.Activation of Latent HIV Using Drug-Loaded NanoparticlesPLoS ONE20116e1827010.1371/journal.pone.001827021483687 161.DuanJ.FreelingJ.P.KoehnJ.ShuC.HoR.J.Y.Evaluation of" exact="Atazanavir" post="and Darunavir Interactions with Lipids for Developing pH-Responsive Anti-HIV"/>
  <result pre="HIV treatmentJ. Nanopart. Res.201315204010.1007/s11051-013-2040-4 180.ReddyP.P.ReddyB.M.PrakashJ.LathaK.PrashanthiD.Formulation and characterisation of chitosan based" exact="lamivudine" post="nanoparticlesEJPMR20144377383 181.SanchezC.G.MolinskiS.V.GongoraR.SosulskiM.FuselierT.MacKinnonS.S.MondalD.LaskyJ.A.The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy"/>
  <result pre="and characterisation of chitosan based lamivudine nanoparticlesEJPMR20144377383 181.SanchezC.G.MolinskiS.V.GongoraR.SosulskiM.FuselierT.MacKinnonS.S.MondalD.LaskyJ.A.The Antiretroviral Agent" exact="Nelfinavir" post="Mesylate: A Potential Therapy for Systemic SclerosisArthritis Rheumatol.20187011512610.1002/art.4032628940894 182.BowmanM.-C.BallardT.E.AckersonC.J.FeldheimD.L.MargolisD.M.MelanderC.Inhibition"/>
  <result pre="Identifier: NCT00270205Available online: https://clinicaltrials.gov/ct2/show/NCT00270205?cond=NCT00270205&amp;amp;draw=2&amp;amp;rank=1(accessed on 18 January 2020) 195.Bioavailability of" exact="MK-1439" post="Experimental Nano Formulations in Healthy Adults (MK-1439-046)-ClinicalTrials.gov Identifier: NCT02549040Available"/>
  <result pre="for the drugs loded on NPs than the free drugs;" exact="Diphyllin" post="and Bafilomycin [138] - Human serum albumin +copolymers of"/>
  <result pre="and DSC; EFV [146] - Folic acid-conjugated-P407 NPs based on" exact="folic acid" post="conjugated with P407 with inclusion of ATV and RTV"/>
 </snippets>
</snippetsTree>
